Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PLEC | Q15149 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586703 | 0.94 | TTR (0.43) | CYP3A4TSHRTDP1TTRAKR1C4 | |
| SCHEMBL31668182 | 0.93 | TTR (0.41) | CYP3A4TSHRTDP1TTRAKR1C4 | |
| SCHEMBL9319479 | 0.93 | TTR (0.41) | CYP3A4TSHRTDP1TTRAKR1C4 | |
| SCHEMBL9319210 | 0.93 | TTR (0.41) | CYP3A4TSHRTDP1TTRAKR1C4 | |
| SCHEMBL6248837 | 0.92 | TTR (0.40) | CYP3A4TSHRTDP1TTRAKR1C4 | |
| SCHEMBL20659945 | 0.88 | TTR (0.41) | CYP3A4TSHRTDP1TTRAKR1C4 | |
| SCHEMBL27515109 | 0.87 | TTR (0.40) | CYP3A4TSHRTDP1TTRAKR1C4 | |
| SCHEMBL7750809 | 0.83 | TTR (0.39) | CYP3A4TSHRTDP1TTRAKR1C4 | |
| SCHEMBL87887 | 0.81 | HCAR2 (0.43) | CYP3A4TSHRTDP1TTRAKR1C4 | |
| SCHEMBL1122760 | 0.81 | HCAR2 (0.43) | CYP3A4TSHRTDP1TTRAKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12295991-B2 | Hemoglobin derivative co-conjugated with fatty acid-linked PEG and alkoxy PEG as a blood substitute | SUNBIO, INC. (KR) | 2025-05-13 | — | — | US | disclosed |
| CN-114341174-B | Succinyl cross-linked hemoglobin analogues and methods of use and preparation thereof | 亿京国际有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11692022-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230111100-A1 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | BILLION KING INTERNATIONAL LIMITED (HK) | 2023-04-13 | — | — | US | disclosed |
| US-11576978-B2 | Hemoglobin-based therapeutic agents | Cheer Global Limited (CN) | 2023-02-14 | — | — | US | disclosed |
| US-20220296685-A1 | Uricase Derivative Co-conjugated With Fatty acid-linked PEG and optionally, Alkoxy PEG | BONE SOLUTIONS, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3999529-A1 | HEMOGLOBIN-BASED THERAPEUTIC AGENTS | Cheer Global Limited (HK) | 2022-05-25 | — | — | EP | disclosed |
| CN-114401983-A | Hemoglobin-based therapeutic agents | 环喜有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2021261712-A1 | HEMOGLOBIN DERIVATIVE CO-CONJUGATED WITH FATTY ACID-LINKED PEG AND ALKOXY PEG AS A BLOOD SUBSTITUTE | SUNBIO, INC. (KR) | 2021-12-30 | — | — | WO | disclosed |
| US-20210401949-A1 | Hemoglobin Derivative Co-conjugated with Fatty Acid-linked PEG and Alkoxy PEG as a Blood Substitute | SUNBIO, INC. (KR) | 2021-12-30 | — | — | US | disclosed |
| US-6054427-A | POLYTHYLENE GLYCOL-MODIFIED HEMOGLOBIN PRESENT IN A CONCENTRATION OF BETWEEN 0.1 AND 4.0 G/DL; SOLUTION HAVING A VISCOSITY AT LEAST HALF THAT OF BLOOD AND AN ONCOTIC PRESSURE HIGHER THAN THAT OF PLASMA. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-04-25 | — | — | US | disclosed |
| WO-1998037909-A9 | METHODS AND COMPOSITIONS FOR OPTIMIZATION OF OXYGEN TRANSPORT BY CELL-FREE SYSTEMS | UNIV CALIFORNIA (US) | 1999-11-18 | — | — | WO | disclosed |
| EP-0361719-B1 | Haemoglobin based blood substitute and method for the preparation thereof | TECHNION RES & DEV FOUNDATION (IL) | 1994-01-12 | — | — | EP | disclosed |
| EP-0562624-A2 | Stabilization of functional proteins | Modrovich, Ivan E. (US) | 1993-09-29 | — | — | EP | disclosed |
| US-5041615-A | Preparation of bis(salicyl) diesters | BAXTER INTERNATIONAL INC. (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0361719-A1 | Haemoglobin based blood substitute and method for the preparation thereof | Technion Research & Development Foundation Ltd. (IL) | 1990-04-04 | — | — | EP | disclosed |
| EP-0143832-B1 | MODIFIED CROSSLINKED STROMA-FREE TETRAMERIC HEMOGLOBIN | TYE, Ross W. (US) | 1989-02-15 | — | — | EP | disclosed |
| EP-0143832-A4 | MODIFIED CROSSLINKED STROMA-FREE TETRAMERIC HEMOGLOBIN. | TYE ROSS W | 1985-09-02 | — | — | EP | disclosed |
| EP-0143832-A1 | MODIFIED CROSSLINKED STROMA-FREE TETRAMERIC HEMOGLOBIN. | TYE ROSS W | 1985-06-12 | — | — | EP | disclosed |
| WO-1984004248-A1 | MODIFIED CROSSLINKED STROMA-FREE TETRAMERIC HEMOGLOBIN | TYE ROSS W | 1984-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11692022-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | HBG1, HBG2, HBB | CYP3A4 818/4885TSHR 653/4885TDP1 3323/4885 |
| US-20230111100-A1 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | HBG1, HBG2, HBB | CYP3A4 818/4885TSHR 653/4885TDP1 3323/4885 |
| US-12295991-B2 | Hemoglobin derivative co-conjugated with fatty acid-linked PEG and alkoxy PEG as a blood substitute | HBG2, HBB, HBG1 | CYP3A4 205/4885TSHR 2592/4885TDP1 4866/4885 |
| US-11576978-B2 | Hemoglobin-based therapeutic agents | HBG1, HBG2, HBB | CYP3A4 2897/4885TSHR 3751/4885TDP1 3553/4885 |
| US-20210401949-A1 | Hemoglobin Derivative Co-conjugated with Fatty Acid-linked PEG and Alkoxy PEG as a Blood Substitute | HBG2, HBB, HBG1 | CYP3A4 205/4885TSHR 2592/4885TDP1 4866/4885 |
| US-20220296685-A1 | Uricase Derivative Co-conjugated With Fatty acid-linked PEG and optionally, Alkoxy PEG | ELOVL3, LIPC, ELOVL6 | CYP3A4 1326/4885TSHR 3018/4885TDP1 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.